BE570545A - - Google Patents
Info
- Publication number
- BE570545A BE570545A BE570545DA BE570545A BE 570545 A BE570545 A BE 570545A BE 570545D A BE570545D A BE 570545DA BE 570545 A BE570545 A BE 570545A
- Authority
- BE
- Belgium
- Prior art keywords
- dimethylamino
- ortho
- meta
- acid addition
- addition salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 238000007792 addition Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 7
- -1 halide ester Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 230000003000 nontoxic Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 230000001225 therapeutic Effects 0.000 claims description 3
- AYNRKIFVNLRLEM-UHFFFAOYSA-N N-[2-(dimethylamino)phenyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CC=CC=2)N(C)C)=C1 AYNRKIFVNLRLEM-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- CJKIGMZTFMJVLO-UHFFFAOYSA-N CN(C)C1=C(C(=O)NC2=CC=CC=C2)C=C(C(=C1OC)OC)OC Chemical compound CN(C)C1=C(C(=O)NC2=CC=CC=C2)C=C(C(=C1OC)OC)OC CJKIGMZTFMJVLO-UHFFFAOYSA-N 0.000 claims 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N Phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000005712 crystallization Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000000147 hypnotic Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001624 sedative Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002936 tranquilizing Effects 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- MBRKSKWYAIWADJ-UHFFFAOYSA-N (2-azaniumylphenyl)-dimethylazanium;dichloride Chemical compound Cl.Cl.CN(C)C1=CC=CC=C1N MBRKSKWYAIWADJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940051881 Anilide analgesics and antipyretics Drugs 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- ADAVSPQFHXXSAR-UHFFFAOYSA-N Cl.CN(C1=C(NC(C2=CC(=C(C(=C2)OC)OC)OC)=O)C=CC=C1)C Chemical compound Cl.CN(C1=C(NC(C2=CC(=C(C(=C2)OC)OC)OC)=O)C=CC=C1)C ADAVSPQFHXXSAR-UHFFFAOYSA-N 0.000 description 1
- 206010014551 Emotional disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 206010057840 Major depression Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- NPZDNLCYFLDJFA-UHFFFAOYSA-N N,N-dimethyl-2-nitroaniline Chemical compound CN(C)C1=CC=CC=C1[N+]([O-])=O NPZDNLCYFLDJFA-UHFFFAOYSA-N 0.000 description 1
- QMQQVOZUPUZQCW-UHFFFAOYSA-N N-[3-(dimethylamino)phenyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C=C(C=CC=2)N(C)C)=C1 QMQQVOZUPUZQCW-UHFFFAOYSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008430 aromatic amides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- CMWYOMQKNDVFMD-UHFFFAOYSA-N benzene;pentane Chemical compound CCCCC.C1=CC=CC=C1 CMWYOMQKNDVFMD-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229930014694 morphine Natural products 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000006487 neurotic disease Diseases 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
Description
<Desc/Clms Page number 1>
L'invention concerne la préparation d'amidesaromatiques d'acides trialcoxybenzoiques possédant une activité thérapeutique.,par exemple comme sédatifs non hypnotiques et calmants cliniques. En particulier, l'invention concerne la préparation d'ortho- et méta-dialkylamino anilides d'acide 3,4,5-trialcoxybenzoi- que.
On peut obtenir les composés préparés suivant la présente invention sous forme de base libre ou de sels d'addition d'acide non toxiques de celle-ci.
La base libre peut être représentée par la formule générale
EMI1.1
où R est un alkyle inférieur et B représente un groupe alkylamino inférieur en po- sition ortho ou méta.
Les substituants alkyle inférieur peuvent représenter un groupe alkyle quelconque à chaîne droite ou ramifiée, à 1 à 6 atomes de carbone. Dans la forme préférée de l'invention, les groupes alkyle inférieur sont des groupes méthyle.
Des exemples de sels d'addition d'acide non toxiques des bases libres préparés à l'aide d'acides organiques ou inorganiques, comprennent le chlorhydra- te, bromhydrate, iodhydrate, sulfate, phosphate, maléate, acétate, citrate, oxala- te, succinate, benzoate, tartrate, fumarate, mandélate, malate, ascorbate et 8- ohlorothéophyllinate.
Les composés préparés suivant la présente invention sont intéressants comme produits pharmaceutiques et comme produits pharmaceutiques intermédiaires.
Plus particulièrement, les composés de la présente invention sont des sédatifs non hypnotiques, et des calmants cliniques utilisés dans des états d'anxiété, neuroses, troubles émotionnels, insomnies, hypertension, etc. Les composés de la présente invention ont également d'autres propriétés thérapeutiques intéressantes comme anesthésiques locaux, analgésiques, et comme activants de remèdes agissant sur le système nerveux central.
Ces composés produisent la rémission dans des cas de dépression psy- choneurotique aiguë et de dépression psychotique aiguëet activent l'action anal- gésique de la morphine et de la codéine en durée et en intensité quand on adminis- tre le composé par voie orale, à une dose journalière de 400 à 2400 mg. Des com- posés de la présente invention règlent la sécrétion d'acide gastrique chez l'homme et les animaux, et réduisent de façon notable la motilité gastrique.
C'est ainsi qu'on peut les utiliser sous forme d'injections intra-péritonales d'une solution aqueuse d'une concentration d'environ 5% en poids sur des rats "Shay" à une dose d'environ la moitié de la dose LD 50-
On prépare aisément les composés de la présente invention en faisant réagir un halogénure, ester ou azide d'acide 3,4,5-trialcoxybenzoique avec 1' ortho- ou méta-dialkylamino inférieur- aniline. Les groupes alkyle inférieurs comprennent des radicaux contenant de un à six atomes de carbone inclus, par exem- ple les groupes méthyle, éthyle, n-propyle, isopropyle, isobutyle, n-amyle, n- hexyle, isohexyl, etc.
Les exemples donnés ci-après illustrent la préparation des composés conformes à la présente invention.
EXEMPLE 1.-
On ajoute lentement à 11 g de méta-diméthylphénylène-diamine, dénommée
<Desc/Clms Page number 2>
également méta-diméthylaminoaniline, dissous dans 100 ml de chloroforme, une solution de 18,8 g de chlorure de 3,4,5-triméthoxybenzoyle dans 100 ml de chloro- forme. On laisse reposer le mélange de réaction à la température ordinaire pendant 90 minutes, on le lave à l'eau et on le sèche sur du carbonate de potassium anhy- dre. On évapore le chloroforme,et obtient comme résidu solide le 3'-diméthylamino- 3,4,5-triméthoxybenzanilide, qu'on fait recristalliser à partir de 100 ml de métha nol, on le dissout dans 200 ml d'acétone et on le décolore par du carbone. Après séparation du carbone, on ajoute de l'acide chlorhydrique.
Par refroidissement, on précipite et recueille 11 g de chlorhydrate de 3'-diméthylamino-3,4,5-trimétho- xybenzanilide, qui fond à 219-220 C.
L'analyse, calculée sur la formule C18H22N204.HC1, donne 59,3% C et 6,30 % H. On trouve 59,2% C et 6,47% H.
EXEMPLE 2. -
On soumet une solution de 25 g (0,15 mole) d'o-nitrodiméthylaniline dans 150 ml de méthanol. à l'hydrogénation sur 9 g de nickel Raney lavé au métha- nol. L'absorption totale d'hydrogène est de 17,6 kg (théoriquement : 18,3 kg). On sépare le catalyseur par filtration et on sature la solution pourpre par de l'acide chlorhydrique sec. On recueille le solide cristallin par aspiration pour précipi- ter 26 g de dichlorhydrate d'o-diméthylaminoaniline cristallisé, qu'on recueille par filtration.
A un mélange agité de 26 g (0,125 mole) de dichlorhydrate d'o-diméthyl aminoaniline et 35 g (0,15 mole) de chlorure de 3,4,5-triméthoxybenzoyle dans 200 ml de chloroforme à la température ordinaire, on ajoute 105 ml (76 g ou 0,75 mole) de triéthylamine en dix minutes. On remue le mélange.et on le chauffe sous reflux pendant quatre heures, on refroidit, on lave trois fois à l'eau et on sépa- re le solvant par distillation dans le vide au bain-marie, pour obtenir 52,3 g de 2'-diméthylamino-3,4,5-triméthoxybenzanilide sous forme d'une huile foncée.
On la dissout dans 1' 'éther et on sature d'acide chlorhydrique sec pour précipiter 51,4 g de chlorhydrate de 2'-diméthylamino-3,4,5-triméthoxybenzanilide. Après re- cristallisation à partir d'acétonitrile puis d'éthanol à 95 % , ce produit fond à 193,5-194,5 C.
L'analyse, calculée sur la formule C18H23ClN2O4, donne 58,9% C et 6,31% H. On trouve 58,86% C et 5,77% H.
On transforme un échantillon de 0,7 g de chlorhydrate en base libre par neutralisation de l'hydroxyde de sodium à 10%, extraction dans de l'éther, et séparation de l'éther par distillation ; on obtient la base sous forme d'une gom- me qui cristallise quand on la triture avec de l'éther de pétrole (Skellysolve B), et qui fond à 96-97,5 C après recristallisation à partir de benzène-n-pentane.
L'analyse , calculée sur la formule C18H22N204,donne 65,4% C et 6,70% H; on trouve : 65,25% C et 6,68% H.
REVENDICATIONS.
**ATTENTION** fin du champ DESC peut contenir debut de CLMS **.
<Desc / Clms Page number 1>
The invention relates to the preparation of aromatic amides of trialkoxybenzoic acids having therapeutic activity, for example as non-hypnotic sedatives and clinical tranquilizers. In particular, the invention relates to the preparation of ortho- and meta-dialkylamino anilides of 3,4,5-trialkoxybenzic acid.
The compounds prepared according to the present invention can be obtained as the free base or as non-toxic acid addition salts thereof.
The free base can be represented by the general formula
EMI1.1
where R is lower alkyl and B represents lower alkylamino group in the ortho or meta position.
The lower alkyl substituents can be any straight chain or branched alkyl group of 1 to 6 carbon atoms. In the preferred form of the invention, the lower alkyl groups are methyl groups.
Examples of non-toxic acid addition salts of free bases prepared using organic or inorganic acids include hydrochloride, hydrobromide, hydrochloride, sulfate, phosphate, maleate, acetate, citrate, oxalate. , succinate, benzoate, tartrate, fumarate, mandelate, malate, ascorbate and 8-ohlorotheophyllinate.
The compounds prepared according to the present invention are useful as pharmaceuticals and as pharmaceutical intermediates.
More particularly, the compounds of the present invention are non-hypnotic sedatives, and clinical tranquilizers used in states of anxiety, neurosis, emotional disorders, insomnia, hypertension, etc. The compounds of the present invention also have other valuable therapeutic properties as local anesthetics, analgesics, and as activators of remedies acting on the central nervous system.
These compounds produce remission in cases of acute psychoneurotic depression and acute psychotic depression and activate the analgesic action of morphine and codeine in duration and intensity when the compound is administered orally, at a daily dose of 400 to 2400 mg. Compounds of the present invention regulate gastric acid secretion in humans and animals, and significantly reduce gastric motility.
Thus, they can be used in the form of intraperitoneal injections of an aqueous solution of a concentration of about 5% by weight in "Shay" rats at a dose of about half the amount. LD 50- dose
The compounds of the present invention are readily prepared by reacting a 3,4,5-trialkoxybenzoic acid halide, ester or azide with ortho- or meta-dialkylamino-lower-aniline. Lower alkyl groups include radicals containing from one to six carbon atoms inclusive, for example methyl, ethyl, n-propyl, isopropyl, isobutyl, n-amyl, n-hexyl, isohexyl, etc.
The examples given below illustrate the preparation of the compounds in accordance with the present invention.
EXAMPLE 1.-
Is slowly added to 11 g of meta-dimethylphenylene diamine, called
<Desc / Clms Page number 2>
also meta-dimethylaminoaniline, dissolved in 100 ml of chloroform, a solution of 18.8 g of 3,4,5-trimethoxybenzoyl chloride in 100 ml of chloroform. The reaction mixture is allowed to stand at room temperature for 90 minutes, washed with water and dried over anhydrous potassium carbonate. The chloroform is evaporated off and the solid residue obtained is 3'-dimethylamino-3,4,5-trimethoxybenzanilide, which is recrystallized from 100 ml of methanol, dissolved in 200 ml of acetone and it is then crystallized. discolored by carbon. After separation of the carbon, hydrochloric acid is added.
On cooling, 11 g of 3'-dimethylamino-3,4,5-trimethoxybenzanilide hydrochloride is precipitated and collected, which melts at 219-220 C.
The analysis, calculated on the formula C18H22N2O4.HC1, gives 59.3% C and 6.30% H. We find 59.2% C and 6.47% H.
EXAMPLE 2. -
A solution of 25 g (0.15 mol) of o-nitrodimethylaniline in 150 ml of methanol is subjected. on hydrogenation on 9 g of Raney nickel washed with methanol. The total absorption of hydrogen is 17.6 kg (theoretically: 18.3 kg). The catalyst is filtered off and the purple solution is saturated with dry hydrochloric acid. The crystalline solid was collected by suction to precipitate 26 g of crystalline o-dimethylaminoaniline dihydrochloride, which was collected by filtration.
To a stirred mixture of 26 g (0.125 mole) of o-dimethyl aminoaniline dihydrochloride and 35 g (0.15 mole) of 3,4,5-trimethoxybenzoyl chloride in 200 ml of chloroform at room temperature is added 105 ml (76 g or 0.75 mol) of triethylamine in ten minutes. The mixture was stirred and heated under reflux for four hours, cooled, washed three times with water and the solvent separated by vacuum distillation on a water bath, to give 52.3 g of. 2'-Dimethylamino-3,4,5-trimethoxybenzanilide as a dark oil.
It was dissolved in ether and saturated with dry hydrochloric acid to precipitate 51.4 g of 2'-dimethylamino-3,4,5-trimethoxybenzanilide hydrochloride. After recrystallization from acetonitrile and then 95% ethanol, this product melts at 193.5-194.5 C.
The analysis, calculated on the formula C18H23ClN2O4, gives 58.9% C and 6.31% H. We find 58.86% C and 5.77% H.
A 0.7 g sample of hydrochloride is converted to the free base by neutralization of 10% sodium hydroxide, extraction with ether, and separation of the ether by distillation; the base is obtained in the form of a gum which crystallizes when triturated with petroleum ether (Skellysolve B), and which melts at 96-97.5 C after recrystallization from benzene-n-pentane .
Analysis, calculated on the formula C18H22N2O4, gives 65.4% C and 6.70% H; we find: 65.25% C and 6.68% H.
CLAIMS.
** ATTENTION ** end of DESC field can contain start of CLMS **.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
BE570545A true BE570545A (en) |
Family
ID=189064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE570545D BE570545A (en) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE570545A (en) |
-
0
- BE BE570545D patent/BE570545A/fr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0487408A1 (en) | Oxazolopyridine derivatives, process for their preparation and pharmaceutical compositions comprising the same | |
FR2526659A1 (en) | IMMUNOMODULANT MEDICAMENTS BASED ON PHENYLACETIC ACID DERIVATIVES | |
EP0073161B1 (en) | Pyridazine derivatives active on the central nerve system | |
EP0092459A2 (en) | Imidazo(1,2-a)pyridines, their preparation and therapeutical use | |
FR2468601A1 (en) | NEW FLAVANNE DERIVATIVES USEFUL IN PARTICULAR AS ANTI-CONVULSANTS | |
CA1088070A (en) | Process for the preparation of novel aminobenzocycloheptene derivatives | |
EP0002978B1 (en) | Thiazolidinedione-2,4 derivatives, their preparation and pharmaceutical applications | |
EP0021940A1 (en) | Amino derivatives of benzothiazole, process for their preparation and their use in therapy | |
CH619935A5 (en) | ||
FR2845991A1 (en) | New alpha phenyl acetanilide derivatives are acyl coenzyme A cholesterol acyltransferase inhibitors used for treating hypercholesterolemia and atherosclerosis | |
EP0000452B1 (en) | 1,2,4-oxadiazol derivatives, their preparation and application in pharmaceutical compositions | |
CH407088A (en) | Process for the preparation of 4-halo-3-sulfamoyl-benzoic acid derivatives | |
CH622795A5 (en) | ||
BE570545A (en) | ||
CA1093582A (en) | Process for the preparation of propylenediamines | |
CH658786A5 (en) | DRUGS THAT CONTAIN ALPHA- (N-PYRROLYL) -ACIDS OR THEIR SALTS OR ESTERS. | |
CA1063619A (en) | Process for the preparation of new benzylamino-acanoic acids ands compounds thereof | |
CH620678A5 (en) | Process for the preparation of a derivative of piperidine | |
EP0106860B1 (en) | New carboxamidoguanidins, method for obtaining them and pharmaceutical compositions containing them | |
FR2526797A1 (en) | NOVEL 9-OXALYSERGIC ACID DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME | |
EP0157762B1 (en) | New substituted piperidinoguanidines, preparation process and pharmaceutical compositions containing them | |
FR2690917A1 (en) | New amino-di:chloro-benzyl-propanol ester cpds. - used to treat depression, neuroses, mood disturbance, migraine, insomnia and nausea | |
CA1064489A (en) | Process for the preparation of new benzenesulfonamides | |
FR2491471A1 (en) | 6-Substd. 2-benzoxazolinone derivs. - useful as analgesics | |
EP0010030A1 (en) | Derivatives of 2'-(ortho-chloro-benzoyl),4'-chloro-glycin anilide, their preparation and their use in medicines |